Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech Gilead Sciences (Nasdaq: GILD ) are rather ill today, down as much as 14% after the company announced intentions to acquire Pharmasset (Nasdaq: VRUS ) .
So what: The deal carries a price tag of roughly $11 billion, or $137 per share, and Gilead is hoping that the company's experimental hepatitis C drugs will make it big. Pharmasset closed at $72.67 on Friday, making the $137 offer a mind-boggling 89% premium. It's no wonder investors are scratching their heads on this deal.
Now what: The deal is expected to hurt Gilead's bottom line through 2014 before becoming accretive. While the acquisition represents a smart direction for the company, the price is way too high. Gilead is paying all cash, which is partially financed by debt, for drug candidates that are still in the pipeline in a deal that dilutes earnings. The addressable market could reach $20 billion by 2020, and Gilead will need to grab a good chunk of that to make this deal worth it.
Interested in more info on Gilead Sciences? Add it to your watchlist by clicking here.
No comments:
Post a Comment